Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.drudis.2013.07.001
10.1016/j.drudis.2013.07.001 · External reference
10.1038/nrd3368
10.1038/nrd3368 · External reference
10.1038/nrd2410
10.1038/nrd2410 · External reference
10.1016/j.bbapap.2018.08.002
10.1016/j.bbapap.2018.08.002 · External reference
10.1038/nrc2559
10.1038/nrc2559 · External reference
10.1016/j.yjmcc.2006.09.005
10.1016/j.yjmcc.2006.09.005 · External reference
10.1111/bcp.13294
10.1111/bcp.13294 · External reference
10.1021/jm5006463
10.1021/jm5006463 · External reference
10.1080/17460441.2018.1413089
10.1080/17460441.2018.1413089 · External reference
10.1038/nrc1691
10.1038/nrc1691 · External reference
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
2019 · External reference
10.1038/nchembio.118
10.1038/nchembio.118 · External reference
10.1038/srep05193
10.1038/srep05193 · External reference
Consistency in drug response profiling
10.1038/nature20171 · 2016 · External reference
10.1038/nmeth.3853
10.1038/nmeth.3853 · External reference
ChEMBL: towards direct deposition of bioassay data
10.1093/nar/gky1075 · 2019 · External reference
Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions
10.1016/j.chembiol.2017.11.009 · 2018 · External reference
10.1242/dmm.021105
10.1242/dmm.021105 · External reference
10.1093/annonc/mdy024
10.1093/annonc/mdy024 · External reference
10.1158/2159-8290.cd-18-1177
10.1158/2159-8290.cd-18-1177 · External reference
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
10.2147/ijwh.s178349 · 2019 · External reference
Triple-negative breast cancer: current understanding and future therapeutic breakthrough targeting cancer stemness
2019 · External reference
10.1038/nrclinonc.2016.66
10.1038/nrclinonc.2016.66 · External reference
10.1200/jco.2007.14.4147
10.1200/jco.2007.14.4147 · External reference
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
10.1186/s12943-016-0517-3 · 2016 · External reference
10.1016/j.chembiol.2019.03.011
10.1016/j.chembiol.2019.03.011 · External reference
10.1038/ng.3984
10.1038/ng.3984 · External reference
10.1016/j.cell.2017.06.010
10.1016/j.cell.2017.06.010 · External reference
10.1038/s41467-019-09799-2
10.1038/s41467-019-09799-2 · External reference
Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
10.1038/s41540-019-0098-z · 2019 · External reference
10.1007/s10565-019-09491-7
10.1007/s10565-019-09491-7 · External reference
10.1186/bcr3192
10.1186/bcr3192 · External reference
10.4048/jbc.2019.22.e39
10.4048/jbc.2019.22.e39 · External reference
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer
10.1158/1078-0432.ccr-13-2166 · 2014 · External reference
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
10.1177/1758835918818346 · 2018 · External reference
10.1158/1078-0432.ccr-17-0369
10.1158/1078-0432.ccr-17-0369 · External reference
Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer
10.1038/s41467-019-10743-7 · 2019 · External reference
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
10.1038/srep35383 · 2016 · External reference
10.1016/j.cell.2015.08.063
10.1016/j.cell.2015.08.063 · External reference
10.1016/j.ccell.2019.09.004
10.1016/j.ccell.2019.09.004 · External reference
10.1038/sj.onc.1207967
10.1038/sj.onc.1207967 · External reference
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
10.1007/s10549-018-4697-y · 2018 · External reference
10.1038/onc.2017.406
10.1038/onc.2017.406 · External reference
10.1038/onc.2016.292
10.1038/onc.2016.292 · External reference
10.1016/j.breast.2016.08.014
10.1016/j.breast.2016.08.014 · External reference
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
10.1186/s13046-019-1206-z · 2019 · External reference
Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
2020 · External reference
10.1038/leu.2016.314
10.1038/leu.2016.314 · External reference
10.1158/2159-8290.cd-13-0350
10.1158/2159-8290.cd-13-0350 · External reference
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens
10.15252/msb.20199405 · 2020 · External reference
Visualizing data using t-SNE
2008 · External reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · External reference
